General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-01 | 2024-06 | 0.01 | N/A | N/A | N/A |
2024-05-02 | 2024-03 | -0.17 | -0.03 | 0.14 | 82.35% |
2024-02-15 | 2023-12 | -0.18 | -0.19 | -0.01 | -5.56% |
2023-11-02 | 2023-09 | -0.17 | -0.09 | 0.08 | 47.06% |
2023-08-03 | 2023-06 | -0.2 | -0.08 | 0.12 | 60.00% |
2023-05-04 | 2023-03 | -0.24 | -0.18 | 0.06 | 25.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-05-02 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-22 | RBC Capital | Upgrade | Outperform | |
2023-01-03 | RBC Capital | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-20 | BALAKRISHNAN BRINDA | Director | 17.52K | Sale |
2024-05-20 | BILLEN DANIEL | Director | 28.14K | Sale |
2024-03-05 | DONLEY MATTHEW MAXWELL | Officer | 584.07K | Sale |
2024-03-05 | GREENLEAF PETER S | Chief Executive Officer | 1.52M | Sale |
2024-03-05 | HABIG SCOTT MICHAEL | Officer | 474.59K | Sale |
2024-05-20 | JAYNE DAVID ROLAND WALKER | Director | 44.36K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 8.33M | 80.66M | 5.81% |
2023-06-29 | Armistice Capital, LLC | 4.69M | 45.42M | 3.27% |
2023-06-29 | NEA Management Company, LLC | 3.97M | 38.43M | 2.77% |
2023-06-29 | State Street Corporation | 2.63M | 25.48M | 1.84% |
2023-06-29 | Goldman Sachs Group Inc | 1.74M | 16.88M | 1.22% |
2023-06-29 | Morgan Stanley | 1.69M | 16.32M | 1.18% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | iShares Russell 2000 ETF | 3.09M | 28.03M | 2.15% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.21M | 13.98M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.13M | 10.28M | 0.79% |
2023-06-29 | College Retirement Equities Fund-Stock Account | 1.10M | 10.67M | 0.77% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 921.41K | 8.36M | 0.64% |
2023-07-30 | TIAA-CREF Funds-Quant Small Cap Equity Fund | 755.87K | 8.75M | 0.53% |
$AUPH I don’t see this patent issue amounting to much, we are lucky to have the holy grail here, need GL to follow up with what he was hired to do…sell the company, let’s see this investor value you promised and totally failed on delivering until this point…
This patent law suit is not going to amount to anything stop with the fear towards investors
Not very many good bios left out there that haven’t been let down by the FDA recently
Sell the company PG
This garbage will be lower tomorrow and the day after that and so on just wait
Fucking margin calls
One drug company and a CEO making millions for 1/2 day a week work come on GL needs to go sell the company you greedy fuck
Never invest in a bio stock with this CEO GL again shit job creating investor value
All events over the past few weeks are complete insider manipulation, why is GL not in the slammer picking up the soap by now, give me his address so his wife will be getting fucked as hard as retail investors